{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T02:44:20Z","timestamp":1788057860016,"version":"build-2784847793"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Magdeburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The study aimed to compare the dosimetric results and treatment delivery efficiency among four techniques to explore the preferred technique in prostate treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>7 IMRT, 9 IMRT, 1 ARC, and 2 ARC plans were created for 30 prostate cancer patients using the Eclipse\u2122 treatment planning system (Varian Medical Systems). All the plans were designed to deliver 80.0\u00a0Gy in 40 fractions to the prostate planning target volume (PTV). Target coverage, organs at risk (OARs), number of monitor units, homogeneity, and conformity were compared across the four techniques to assess the quality of the plans.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study revealed better Planning Target Volume (PTV) dose coverage in the VMAT-2A than in the other plans. At the same time, VMAT-2A plans were found to be significantly lower in terms of Bladder and rectum doses than other techniques. In addition, VMAT has the advantage of considerably reducing the number of monitor units and treatment time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>For prostate cancer, VMAT may offer a favorable dose gradient profile, conformity, and MU and treatment time compared to IMRT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-023-04586-5","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T03:02:56Z","timestamp":1674788576000},"page":"6239-6246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Analytical dosimetric study of intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) for prostate cancer"],"prefix":"10.1007","volume":"149","author":[{"given":"Fady","family":"Samir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talaat M.","family":"Meaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathi AEl","family":"Hussiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr A.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Refaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Gawish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abouegylah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"4586_CR1","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/j.ijrobp.2008.06.986","volume":"72","author":"V Beckendorf","year":"2008","unstructured":"Beckendorf V, Guerif S, Le Prise E, Cosset J, Bougnoux A et al (2008) 70 Gy versus (vs) 80 Gy dose escalation Getug 06 French trial for localized prostate cancer: mature results. Int J Radiat Oncol Biol Phys 72:S96\u2013S97","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4586_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","volume":"360","author":"M Bolla","year":"2002","unstructured":"Bolla M, Collette L, Blank L, Warde P, Dubois JB et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103\u2013106","journal-title":"Lancet"},{"key":"4586_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.canrad.2004.09.003","volume":"8","author":"I Chauvet","year":"2004","unstructured":"Chauvet I, Gaboriaud G, Pontvert D, Zefkili S, Giraud P et al (2004) Constraints and dosage for prostate cancer patients treated with conformal radiotherapy and intensity modulated radiation therapy. Cancer Radiother 8:337\u2013351","journal-title":"Cancer Radiother"},{"key":"4586_CR4","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969\u2013974","journal-title":"JAMA"},{"key":"4586_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/jama.292.7.821","volume":"292","author":"AV D\u2019Amico","year":"2004","unstructured":"D\u2019Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A et al (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292:821\u2013827","journal-title":"JAMA"},{"key":"4586_CR6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(05)70348-X","volume":"6","author":"JW Denham","year":"2005","unstructured":"Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H et al (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6:841\u2013850","journal-title":"Lancet Oncol"},{"key":"4586_CR7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/0360-3016(93)90399-G","volume":"27","author":"JM Galvin","year":"1993","unstructured":"Galvin JM, Chen XG, Smith RM (1993) Combining multileaf fields to modulate fluence distributions. Int J Radiat Oncol Biol Phys 27:697\u2013705","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4586_CR8","doi-asserted-by":"publisher","first-page":"20130199","DOI":"10.1259\/bjr.20130199","volume":"86","author":"K Ishii","year":"2013","unstructured":"Ishii K, Ogino R, Okada W, Nakahara R, Kawamorita R et al (2013) A dosimetric comparison of RapidArc and IMRT with hypofractionated simultaneous integrated boost to the prostate for treatment of prostate cancer. Br J Radiol 86:20130199","journal-title":"Br J Radiol"},{"issue":"5","key":"4586_CR9","first-page":"1","volume":"14","author":"R Lange Abu-Hijlih","year":"2020","unstructured":"Lange Abu-Hijlih R, Afifi S, Almousa A, Khader J, Alhajal W, AlRjoub I et al (2020) Volumetric-modulated arc therapy versus intensity-modulated radiotherapy for localized prostate cancer: a dosimetric comparative analysis of moderate hypofractionated radiation. Oncol Radiother 14(5):1\u20135","journal-title":"Oncol Radiother"},{"issue":"2","key":"4586_CR10","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ijrobp.2009.08.032","volume":"77","author":"MM Matuszak","year":"2010","unstructured":"Matuszak MM, Yan D, Grills I, Martinez A (2010) Clinical applications of volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 77(2):608\u2013616. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.08.032","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"4586_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1017\/S1460396920000370","volume":"20","author":"R Mukhtar","year":"2021","unstructured":"Mukhtar R, Butt S, Rafaye MA, Iqbal K, Mazhar S, Sadaf T (2021) An institutional review: dosimetry comparison between simultaneous integrated boost IMRT and VMAT for prostate cancer. J Radiother Pract 20(3):321\u2013331","journal-title":"J Radiother Pract"},{"key":"4586_CR12","doi-asserted-by":"publisher","first-page":"e657","DOI":"10.1016\/j.ijrobp.2011.09.006","volume":"82","author":"S Myerhaug","year":"2012","unstructured":"Myerhaug S, Chan G, Craig T, Weinberg V, Cheng C, Roach M 3rd et al (2012) A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 82:e657\u2013e662","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4586_CR13","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","volume":"24","author":"ST Peeters","year":"2006","unstructured":"Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J ClinOncol 24:1990\u20131996","journal-title":"J ClinOncol"},{"issue":"2","key":"4586_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10(2):63\u201389","journal-title":"World J Oncol"},{"key":"4586_CR15","first-page":"611","volume":"55","author":"C Sale","year":"2011","unstructured":"Sale C, Moloney P (2011) Dose comparisons for conformal, IMRT and VMAT prostate plans. J Med Imaging RadiatOncol 55:611\u2013621","journal-title":"J Med Imaging RadiatOncol"},{"key":"4586_CR16","doi-asserted-by":"publisher","first-page":"S312","DOI":"10.1016\/j.ijrobp.2005.07.536","volume":"63","author":"AW Su","year":"2005","unstructured":"Su AW, Milano MT, Jani AB (2005) IMRT versus conventional whole pelvis radiotherapy for prostate cancer: planning comparison and analysis of acute toxicity. Int J Radiat Oncol Biol Phys 63:S312\u2013S313","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"4586_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"4586_CR18","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1088\/0031-9155\/37\/8\/005","volume":"37","author":"S Webb","year":"1992","unstructured":"Webb S (1992) Optimization by simulated annealing of three- dimensional, conformal treatment planning for radiation fields defined by a multileaf collimator: II. Inclusion of two-dimensional modulation of the x-ray intensity. Phys Med Biol 37:1689\u20131704","journal-title":"Phys Med Biol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04586-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04586-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04586-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T12:18:40Z","timestamp":1689769120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04586-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4586"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04586-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]},"assertion":[{"value":"9 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}